SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICN Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: debra vogt who wrote (766)3/10/1998 6:18:00 PM
From: Carl Wysocki  Respond to of 1029
 
The contrarian in me wants to say that this is bad news. Somehow
Wall Street didn't recognize this company until it had more than tripled
in price, and all of a sudden it's now attractive.

But, here's hoping a few more of those laggards jump on board to
acknowledge what many of have known for quite some time,
painful as it seemed until about 12 months ago.

I'm writing calls in dribs and drabs, more to pare my ICN holdings
as they get too large a position than any lack of belief in the fundamentals. I thought when I wrote Jun 60s a few weeks ago
for 5, that I would make money. Today, I couldn't resist the June
65s at 7. Oh well, there is the national debt to pay off, and I may
end up contributing to its demise.

Carl



To: debra vogt who wrote (766)3/11/1998 3:09:00 PM
From: Clouseau  Read Replies (1) | Respond to of 1029
 
Debra/Mike - I understand that the Goldman 12 month price target is $100. Based on the participation in the concall by Dillon Reed, Solomon Smith Barney and Hambrecht Quist, maybe we will see more recommendations.

Dave


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News